Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lexicon Pharmaceuticals, Inc. (LXRX)
USD2.07
-0.06 (-2.59%)
US NASDAQ Healthcare Biotechnology
Address
2445 Technology Forest Boulevard 77381
The Woodlands, TX, US
The Woodlands, TX, US
CEO
Michael S. Exton
Website
lexpharma.com
IPO
2000-04-07
CIK 1062822 ISIN US5288723027
Description
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.07
-0.06 (-2.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.05
Float Shares
179.78M
Free Float %
42.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +15.50% | +40.00% | +34.30% | +76.34% | +50.00% | +100.87% | +242.78% | -19.51% | -47.26% | -80.42% | -98.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Hold
Price Targets & DCF
Current price
2.07
Low
6.00
+190.6%
Consensus
6.00
+190.6%
Median
6.00
+190.6%
High
6.00
+190.6%
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
6.00
+190.6%
|
| Last Year | 1 |
6.00
+190.6%
|
| All Time | 2 |
6.00
+190.6%
|
Quality scores
Altman Z-Score
-0.39
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+60.2% ★ Q1'26: +1,572.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+77.8% ★ Q1'26: +96.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-167.7% Q1'26: -69.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-98.2% Q1'26: -4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-66.5% Q1'26: -4.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.4% Q1'26: +10.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.29× Q1'26: -14.48× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.91M
est: 4.96M (-1.1%)
|
1.85M
est: 1.80M (+2.5%)
|
1.09M
est: 1.19M (-8.6%)
|
2.22M
est: 3.16M (-29.6%)
|
130.01M
est: 3.09M (+4,106.9%)
|
83.34M
est: 77.13M (+8.1%)
|
90.34M
est: 86.39M (+4.6%)
|
63.21M
est: 58.13M (+8.7%)
|
322.07M
est: 323.41M (-0.4%)
|
24.00M
est: 156.75M (-84.7%)
|
298.0K
est: 194.7K (+53.1%)
|
139.0K
est: 137.0K (+1.5%)
|
1.20M
est: 3.64M (-66.9%)
|
31.08M
est: 11.13M (+179.2%)
|
49.80M
est: 47.46M (+4.9%)
|
38.16M
35.86M – 40.01M
-19.6% YoY
|
20.15M
14.02M – 26.29M
-47.2% YoY
|
70.08M
69.42M – 70.74M
+247.7% YoY
|
99.39M
82.37M – 114.14M
+41.8% YoY
|
107.82M
89.36M – 123.82M
+8.5% YoY
|
| EBITDA |
-93.69M
est: -93.05M (-0.7%)
|
-108.80M
est: -98.24M (-10.8%)
|
-103.91M
est: -112.57M (+7.7%)
|
-99.29M
est: -130.44M (+23.9%)
|
11.72M
est: -3.09M (+479.2%)
|
-125.82M
est: -77.13M (-63.1%)
|
-125.27M
est: -163.80M (+23.5%)
|
-96.09M
est: -58.13M (-65.3%)
|
148.45M
est: -323.41M (+145.9%)
|
-41.10M
est: -156.75M (+73.8%)
|
-86.80M
est: -95.37M (+9.0%)
|
-100.03M
est: -95.87M (-4.3%)
|
-169.76M
est: -3.62M (-4,590.8%)
|
-184.29M
est: -11.06M (-1,565.6%)
|
-48.29M
est: -47.17M (-2.4%)
|
-37.93M
-39.77M – -35.64M
+19.6% YoY
|
-20.03M
-26.13M – -13.93M
+47.2% YoY
|
-69.65M
-70.31M – -68.99M
-247.7% YoY
|
-98.79M
-113.44M – -81.87M
-41.8% YoY
|
-107.17M
-123.07M – -88.81M
-8.5% YoY
|
| EBIT |
-99.08M
est: -95.11M (-4.2%)
|
-113.69M
est: -103.10M (-10.3%)
|
-108.10M
est: -117.47M (+8.0%)
|
-102.16M
est: -134.23M (+23.9%)
|
10.99M
est: -3.09M (+455.7%)
|
-124.88M
est: -77.13M (-61.9%)
|
-128.67M
est: -170.51M (+24.5%)
|
-99.77M
est: -58.13M (-71.6%)
|
144.80M
est: -323.41M (+144.8%)
|
-44.03M
est: -156.75M (+71.9%)
|
-87.09M
est: -95.72M (+9.0%)
|
-100.46M
est: -96.24M (-4.4%)
|
-170.31M
est: -3.63M (-4,594.4%)
|
-184.82M
est: -11.09M (-1,566.2%)
|
-48.91M
est: -47.29M (-3.4%)
|
-38.03M
-39.86M – -35.73M
+19.6% YoY
|
-20.08M
-26.19M – -13.97M
+47.2% YoY
|
-69.82M
-70.48M – -69.17M
-247.7% YoY
|
-99.04M
-113.73M – -82.07M
-41.8% YoY
|
-107.44M
-123.37M – -89.04M
-8.5% YoY
|
| Net Income |
-101.78M
est: -101.10M (-0.7%)
|
-116.22M
est: -105.07M (-10.6%)
|
-110.21M
est: -119.42M (+7.7%)
|
-104.13M
est: -136.49M (+23.7%)
|
-4.68M
est: -409.64M (+98.9%)
|
-141.43M
est: -494.45M (+71.4%)
|
-129.05M
est: -160.96M (+19.8%)
|
-120.55M
est: -407.95M (+70.5%)
|
130.13M
est: 290.79M (-55.2%)
|
-58.57M
est: -236.71M (+75.3%)
|
-87.76M
est: -96.45M (+9.0%)
|
-101.94M
est: -130.72M (+22.0%)
|
-177.12M
est: -276.19M (+35.9%)
|
-200.40M
est: -244.65M (+18.1%)
|
-50.34M
est: -60.61M (+16.9%)
|
-57.75M
-60.79M – -54.72M
+4.7% YoY
|
-91.47M
-94.42M – -50.84M
-58.4% YoY
|
-27.41M
-61.66M – 6.85M
+70.0% YoY
|
-10.89M
-12.99M – -8.47M
+60.3% YoY
|
-9.68M
-11.55M – -7.53M
+11.1% YoY
|
| SGA |
22.57M
est: 6.17M (+266.0%)
|
17.35M
est: 2.24M (+673.9%)
|
17.04M
est: 1.48M (+1,050.9%)
|
17.12M
est: 3.92M (+336.5%)
|
23.84M
est: 3.84M (+520.7%)
|
43.04M
est: 95.82M (-55.1%)
|
66.20M
est: 82.77M (-20.0%)
|
63.75M
est: 72.22M (-11.7%)
|
56.84M
est: 401.81M (-85.9%)
|
47.23M
est: 194.76M (-75.7%)
|
—
est: 241.9K (-100.0%)
|
—
est: 170.2K (-100.0%)
|
—
est: 3.64M (-100.0%)
|
131.90M
est: 11.12M (+1,086.5%)
|
37.32M
est: 47.39M (-21.3%)
|
38.11M
35.81M – 39.95M
-19.6% YoY
|
20.13M
14.00M – 26.25M
-47.2% YoY
|
69.98M
69.32M – 70.64M
+247.7% YoY
|
99.26M
82.26M – 113.98M
+41.8% YoY
|
107.67M
89.23M – 123.65M
+8.5% YoY
|
| EPS |
-2.35
est: -2.19 (-7.6%)
|
-2.39
est: -2.13 (-12.2%)
|
-1.58
est: -1.84 (+14.1%)
|
-1.42
est: -1.37 (-4.0%)
|
-0.05
est: -1.28 (+96.5%)
|
-1.36
est: -1.55 (+12.0%)
|
-1.23
est: -1.35 (+9.0%)
|
-1.14
est: -1.27 (+10.6%)
|
1.23
est: 0.91 (+35.4%)
|
-0.63
est: -0.74 (+14.8%)
|
-0.61
est: -0.61 (-0.8%)
|
-0.62
est: -0.56 (-10.1%)
|
-0.80
est: -0.77 (-3.6%)
|
-0.63
est: -0.68 (+7.2%)
|
-0.14
est: -0.17 (+16.1%)
|
-0.16
-0.17 – -0.15
+4.7% YoY
|
-0.20
-0.26 – -0.14
-25.8% YoY
|
-0.10
-0.17 – 0.02
+49.3% YoY
|
-0.03
-0.04 – -0.02
+70.4% YoY
|
-0.03
-0.03 – -0.02
+11.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-34.30M
OE per share TTM
-0.09
Owner's Yield
-5.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
25
Total invested
1.43M
Insider transactions (90d)
7
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 38.69M | 10.70% | — | — | 38.69M | — | IN | Delaware | 2024-07-10 | ↗ |
| 2 | FMR LLC | 38.69M | 10.70% | 38.68M | — | 38.69M | — | HC | Delaware | 2024-07-10 | ↗ |
| 3 | Edward C. Johnson 3d | 34.24M | 13.00% | — | — | 34.24M | — | IN | Delaware | 2010-04-12 | ↗ |
| 4 | (. | 20.39M | 19.90% | 20.39M | — | 20.39M | 10.00 | OO | Citizenship or Place of Organization | 2007-06-27 | ↗ |
| 5 | Raymond Debbane | 20.39M | 19.90% | 20.39M | — | 20.39M | 10.00 | IN | Citizenship or Place of Organization | 2007-06-27 | ↗ |
| 6 | BVF Inc. | 10.96M | 7.80% | — | — | — | 10.96M | CO | Delaware | 2020-12-21 | ↗ |
| 7 | BVF Partners L.P. | 10.96M | 7.80% | — | — | — | 10.96M | IA, PN | Delaware | 2020-12-21 | ↗ |
| 8 | Mark N. Lampert | 10.96M | 7.80% | — | — | — | 10.96M | IN | Delaware | 2020-12-21 | ↗ |
| 9 | BVF GP HOLDINGS LLC | 10.05M | 7.10% | — | — | — | 10.05M | OO | Delaware | 2020-12-21 | ↗ |
| 10 | 52-0556948 | 8.96M | 5.00% | 2.13M | — | 8.96M | — | IA | MARYLAND | 2010-02-11 | ↗ |
| 11 | Biotechnology Value Fund, L.P. | 7.56M | 5.10% | — | 7.56M | — | 7.56M | PN | Delaware | 2022-02-14 | ↗ |
| 12 | Fidelity Growth Company Fund | 6.48M | 6.23% | 6.48M | — | — | — | IV | Delaware | 2017-02-14 | ↗ |
| 13 | BVF I GP LLC | 5.79M | 4.10% | — | — | — | 5.79M | OO | Delaware | 2020-12-21 | ↗ |
| 14 | Harri V. Taranto | 5.33M | 6.20% | — | 5.33M | — | 5.33M | IN | United States | 2007-06-25 | ↗ |
| 15 | Mark Kessel | 5.33M | 6.20% | — | 5.33M | — | 5.33M | IN | United States | 2007-06-25 | ↗ |
| 16 | Neil J. Sandler | 5.33M | 6.20% | — | 5.33M | — | 5.33M | IN | United States | 2007-06-25 | ↗ |
| 17 | Symphony Capital GP, L.P. | 4.95M | 5.80% | 4.95M | — | 4.95M | — | PN | Delaware | 2007-06-25 | ↗ |
| 18 | Symphony Capital Partners, L.P. | 4.95M | 5.80% | 4.95M | — | 4.95M | — | PN | Delaware | 2007-06-25 | ↗ |
| 19 | Symphony GP, LLC | 4.95M | 5.80% | 4.95M | — | 4.95M | — | OO | Delaware | 2007-06-25 | ↗ |
| 20 | BVF II GP LLC | 4.26M | 3.00% | — | — | — | 4.26M | OO | Delaware | 2020-12-21 | ↗ |
| 21 | Biotechnology Value Fund II, L.P. | 4.26M | 3.00% | — | — | — | 4.26M | PN | Delaware | 2020-12-21 | ↗ |
| 22 | Arthur T. Sands, M.D., Ph.D. | 3.80M | 5.70% | 3.80M | — | 3.80M | — | IN | United States | 2005-02-11 | ↗ |
| 23 | (: | 3.46M | 6.30% | 3.46M | — | 3.46M | — | IN | United States | 2003-02-13 | ↗ |
| 24 | Invus Public Equities Advisors, L.L.C. 98-0420201 | 3.30M | 5.11% | — | 3.30M | — | 3.30M | OO | Delaware | 2006-03-09 | ↗ |
| 25 | Invus Public Equities, L.P. 98-0420215 | 3.30M | 5.11% | — | 3.30M | — | 3.30M | PN | Bermuda | 2006-03-09 | ↗ |
| 26 | Ulys, L.L.C. 83-0359139 | 3.30M | 5.11% | — | 3.30M | — | 3.30M | OO | Delaware | 2006-03-09 | ↗ |
| 27 | BVF Partners OS Ltd. | 704.4K | 1.00% | — | — | — | 704.4K | OO | Delaware | 2020-12-21 | ↗ |
| 28 | Biotechnology Value Trading Fund OS LP | 704.4K | 1.00% | — | — | — | 704.4K | PN | Delaware | 2020-12-21 | ↗ |
| 29 | Symphony Strategic Partners, LLC | 374.9K | 0.40% | 374.9K | — | 374.9K | — | OO | Delaware | 2007-06-25 | ↗ |
| 30 | 98-0186363 | 98.00 | 4.01% | — | — | — | — | HC | Switzerland | 2019-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
25
-102 vs prev Q
New positions
1
Closed positions
98
Increased
4
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 880.0K +880.0K (+100.0%) | 1.01B +1.0B (+100.0%) | 0.24% +0.242 pp | 1.16% +1.157 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 2 | ARTAL GROUP S.A. | 136.18M +— (+0.0%) | 156.61M -27.2M (-14.8%) | 37.47% -0.011 pp | 21.91% -2.332 pp | USD4.21 -72.7% | 43 qtrs — |
| 3 | SIREN, L.L.C. | 38.92M +— (+0.0%) | 44.76M -7.8M (-14.8%) | 10.71% -0.003 pp | 1.34% -0.720 pp | USD1.57 -26.8% | 6 qtrs — |
| 4 | FMR LLC | 37.83M -845.5K (-2.2%) | 43.51M -8.7M (-16.7%) | 10.41% -0.236 pp | 0.00% -0.001 pp | USD1.84 -37.5% | 43 qtrs — |
| 5 | VANGUARD GROUP INC | 9.61M +84.7K (+0.9%) | 11.05M -1.8M (-14.1%) | 2.64% +0.023 pp | 0.00% +0.000 pp | USD3.26 -64.7% | 43 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 4.82M +991.1K (+25.9%) | 5.54M +373.6K (+7.2%) | 1.33% +0.272 pp | 0.00% +0.000 pp | USD1.17 -1.7% | 3 qtrs — |
| 7 | BLACKROCK, INC. | 3.19M -202.5K (-6.0%) | 3.67M -911.9K (-19.9%) | 0.88% -0.056 pp | 0.00% +0.000 pp | USD1.55 -25.8% | 6 qtrs — |
| 8 | UBS GROUP AG | 3.01M +2.7M (+752.1%) | 3.46M +3.0M (+625.9%) | 0.83% +0.730 pp | 0.00% +0.001 pp | USD1.09 +5.5% | 43 qtrs — |
| 9 | SESSA CAPITAL IM, L.P. | 3.00M +— (+0.0%) | 3.45M -600.0K (-14.8%) | 0.83% 0.000 pp | 0.06% -0.031 pp | USD0.95 +21.1% | 3 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.50M +102.1K (+4.3%) | 2.88M -361.8K (-11.2%) | 0.69% +0.028 pp | 0.00% +0.000 pp | USD3.27 -64.8% | 43 qtrs — |
| 11 | CIBC PRIVATE WEALTH GROUP, LLC | 1.95M -450.3K (-18.8%) | 2.24M -997.8K (-30.8%) | 0.54% -0.124 pp | 0.00% -0.002 pp | USD0.50 +130.0% | 14 qtrs — |
| 12 | MARSHALL WACE, LLP | 1.26M +1.3M (+100.0%) | 1.45M +1.5M (+100.0%) | 0.35% +0.347 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.06M -89.5K (-7.8%) | 1.21M -331.9K (-21.5%) | 0.29% -0.025 pp | 0.00% 0.000 pp | USD3.03 -62.0% | 43 qtrs — |
| 14 | GSA CAPITAL PARTNERS LLP | 996.2K -206.7K (-17.2%) | 1.15M -478.0K (-29.4%) | 0.27% -0.057 pp | 0.10% -0.037 pp | USD0.81 +42.0% | 4 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 921.2K +861.9K (+1,452.2%) | 1.06M +979.3K (+1,222.3%) | 0.25% +0.237 pp | 0.00% +0.000 pp | USD1.19 -3.4% | 43 qtrs — |
| 16 | HENNION & WALSH ASSET MANAGEMENT, INC. | 901.2K +122.0K (+15.7%) | 1.04M -15.5K (-1.5%) | 0.25% +0.034 pp | 0.04% -0.002 pp | USD1.46 -21.2% | 7 qtrs — |
| 17 | STATE STREET CORP | 884.7K +4.6K (+0.5%) | 1.02M -170.7K (-14.4%) | 0.24% +0.001 pp | 0.00% +0.000 pp | USD4.46 -74.2% | 43 qtrs — |
| 18 | TWO SIGMA INVESTMENTS, LP | 637.3K +78.3K (+14.0%) | 732.9K -21.8K (-2.9%) | 0.18% +0.022 pp | 0.00% 0.000 pp | USD1.07 +7.5% | 3 qtrs — |
| 19 | ACADIAN ASSET MANAGEMENT LLC | 640.1K +603.2K (+1,634.5%) | 732.0K +683.0K (+1,393.9%) | 0.18% +0.166 pp | 0.00% +0.001 pp | USD1.16 -0.9% | 6 qtrs — |
| 20 | INVESCO LTD. | 594.9K +73.5K (+14.1%) | 684.1K -19.8K (-2.8%) | 0.16% +0.020 pp | 0.00% +0.000 pp | USD1.02 +12.7% | 23 qtrs — |
| 21 | CITADEL ADVISORS LLC | 472.8K +115.2K (+32.2%) | 543.7K +61.0K (+12.6%) | 0.13% +0.032 pp | 0.00% +0.000 pp | USD1.05 +9.5% | 36 qtrs — |
| 22 | NORTHERN TRUST CORP | 412.2K +42.4K (+11.5%) | 474.0K -25.2K (-5.1%) | 0.11% +0.012 pp | 0.00% +0.000 pp | USD3.76 -69.4% | 43 qtrs — |
| 23 | COMPAGNIE LOMBARD ODIER SCMA | 410.0K +— (+0.0%) | 471.5K -82.0K (-14.8%) | 0.11% +0.000 pp | 0.01% -0.001 pp | USD1.32 -12.9% | 41 qtrs — |
| 24 | POINT72 ASSET MANAGEMENT, L.P. | 284.0K +284.0K (+100.0%) | 326.6K +326.6K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 25 | OMERS ADMINISTRATION CORP | 273.8K +273.8K (+100.0%) | 314.9K +314.9K (+100.0%) | 0.08% +0.075 pp | 0.00% +0.002 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 26 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 268.4K +268.4K (+100.0%) | 308.7K +308.7K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.002 pp | USD1.15 +0.0% | 3 qtrs — |
| 27 | RENAISSANCE TECHNOLOGIES LLC | 263.3K -29.1K (-10.0%) | 302.7K -92.0K (-23.3%) | 0.07% -0.008 pp | 0.00% 0.000 pp | USD1.35 -14.8% | 2 qtrs — |
| 28 | GROUP ONE TRADING, L.P. | 224.3K +8.1K (+3.7%) | 258.0K -34.0K (-11.6%) | 0.06% +0.002 pp | 0.00% 0.000 pp | USD0.72 +59.7% | 5 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 199.9K +84.1K (+72.6%) | 229.9K +73.6K (+47.1%) | 0.06% +0.023 pp | 0.00% +0.000 pp | USD0.93 +23.7% | 42 qtrs — |
| 30 | BARCLAYS PLC | 194.7K +870.0 (+0.4%) | 224.0K -80.4K (-26.4%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.36 -15.4% | 43 qtrs — |
| 31 | MORGAN STANLEY | 193.0K +24.0K (+14.2%) | 222.0K -6.2K (-2.7%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD1.32 -12.9% | 43 qtrs — |
| 32 | TWO SIGMA ADVISERS, LP | 181.0K +181.0K (+100.0%) | 208.1K +208.1K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 33 | IKARIAN CAPITAL, LLC | 164.7K -11.8K (-6.7%) | 189.4K -48.9K (-20.5%) | 0.05% -0.003 pp | 0.01% -0.009 pp | USD0.74 +55.4% | 5 qtrs — |
| 34 | CERITY PARTNERS LLC | 144.9K -13.1K (-8.3%) | 166.7K -46.7K (-21.9%) | 0.04% -0.004 pp | 0.00% 0.000 pp | USD0.84 +36.9% | 8 qtrs — |
| 35 | AQR CAPITAL MANAGEMENT LLC | 144.8K -158.1K (-52.2%) | 166.5K -242.4K (-59.3%) | 0.04% -0.044 pp | 0.00% 0.000 pp | USD0.54 +113.0% | 4 qtrs — |
| 36 | HEADLANDS TECHNOLOGIES LLC | 136.1K +86.5K (+174.2%) | 156.5K +89.5K (+133.5%) | 0.04% +0.024 pp | 0.01% +0.008 pp | USD1.22 -5.7% | 2 qtrs — |
| 37 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 126.6K +126.6K (+100.0%) | 145.6K +145.6K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.004 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 38 | HRT FINANCIAL LP | 117.5K +71.1K (+153.1%) | 135.0K +73.0K (+117.7%) | 0.03% +0.020 pp | 0.00% +0.000 pp | USD1.07 +7.5% | 3 qtrs — |
| 39 | MONACO ASSET MANAGEMENT SAM | 117.2K -232.8K (-66.5%) | 134.8K -337.7K (-71.5%) | 0.03% -0.064 pp | 0.02% -0.005 pp | USD0.46 +150.0% | 4 qtrs — |
| 40 | TWO SIGMA SECURITIES, LLC | 114.6K +98.8K (+621.8%) | 131.8K +110.4K (+514.9%) | 0.03% +0.027 pp | 0.02% +0.015 pp | USD1.12 +2.7% | 3 qtrs — |
| 41 | GRAHAM CAPITAL MANAGEMENT, L.P. | 109.9K +109.9K (+100.0%) | 126.4K +126.4K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.003 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 42 | JANE STREET GROUP, LLC | 104.1K +104.1K (+100.0%) | 119.7K +119.7K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 3 qtrs — |
| 43 | BANK OF AMERICA CORP /DE/ | 102.1K +44.3K (+76.6%) | 117.4K +39.4K (+50.5%) | 0.03% +0.012 pp | 0.00% +0.000 pp | USD1.33 -13.5% | 43 qtrs — |
| 44 | HUDSON BAY CAPITAL MANAGEMENT LP | 100.5K +100.5K (+100.0%) | 115.6K +115.6K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 3 qtrs — |
| 45 | XTX TOPCO LTD | 96.1K -233.4K (-70.8%) | 110.5K -334.4K (-75.2%) | 0.03% -0.064 pp | 0.00% -0.020 pp | USD1.25 -8.0% | 6 qtrs — |
| 46 | JEFFERIES FINANCIAL GROUP INC. | 92.5K -4.9K (-5.0%) | 106.4K -25.1K (-19.1%) | 0.03% -0.001 pp | 0.00% 0.000 pp | USD1.35 -14.8% | 2 qtrs — |
| 47 | CITIGROUP INC | 91.7K +73.6K (+405.9%) | 105.4K +81.0K (+331.0%) | 0.03% +0.020 pp | 0.00% +0.000 pp | USD1.21 -5.0% | 43 qtrs — |
| 48 | QUARRY LP | 88.0K +88.0K (+100.0%) | 101.2K +101.2K (+100.0%) | 0.02% +0.024 pp | 0.02% +0.016 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 49 | LPL FINANCIAL LLC | 87.1K -4.2K (-4.6%) | 100.1K -23.1K (-18.7%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD1.47 -21.8% | 16 qtrs — |
| 50 | CAXTON ASSOCIATES LLP | 71.0K +71.0K (+100.0%) | 81.7K +81.7K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.002 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 51 | BANK OF MONTREAL /CAN/ | 70.0K +— (+0.0%) | 80.5K -14.0K (-14.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.55 -25.8% | 8 qtrs — |
| 52 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 66.6K +— (+0.0%) | 76.6K -13.3K (-14.8%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD1.03 +11.7% | 9 qtrs — |
| 53 | STRAIGHT PATH WEALTH MANAGEMENT | 62.7K +— (+0.0%) | 72.1K -12.5K (-14.8%) | 0.02% +0.000 pp | 0.02% -0.003 pp | USD0.46 +150.0% | 4 qtrs — |
| 54 | STATE OF WYOMING | 60.6K +52.0K (+610.4%) | 69.7K +58.1K (+505.2%) | 0.02% +0.014 pp | 0.01% +0.006 pp | USD1.18 -2.5% | 2 qtrs — |
| 55 | SQUAREPOINT OPS LLC | 60.5K +1.8K (+3.1%) | 69.5K -9.7K (-12.2%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD0.48 +139.6% | 6 qtrs — |
| 56 | OPTIVER HOLDING B.V. | 52.6K -23.3K (-30.7%) | 60.5K -42.0K (-41.0%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD1.33 -13.5% | 7 qtrs — |
| 57 | FORTIS GROUP ADVISORS, LLC | 50.0K -7.8K (-13.5%) | 58.0K -21.8K (-27.3%) | 0.01% -0.002 pp | 0.01% -0.004 pp | USD0.63 +82.5% | 4 qtrs — |
| 58 | R SQUARED LTD | 46.6K +14.5K (+45.3%) | 53.6K +10.3K (+23.8%) | 0.01% +0.004 pp | 0.03% +0.006 pp | USD1.03 +11.7% | 5 qtrs — |
| 59 | BOOTHBAY FUND MANAGEMENT, LLC | 44.3K -11.8K (-21.0%) | 51.0K -24.8K (-32.7%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD0.74 +55.4% | 5 qtrs — |
| 60 | WEDBUSH SECURITIES INC | 40.9K +— (+0.0%) | 47.0K -8.0K (-14.5%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD2.28 -49.6% | 8 qtrs — |
| 61 | KWB WEALTH | 40.6K +— (+0.0%) | 46.7K +8.3K (+21.6%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.53 -24.8% | 9 qtrs — |
| 62 | CATALYST FUNDS MANAGEMENT PTY LTD | 40.3K +— (+0.0%) | 46.3K -8.1K (-14.8%) | 0.01% +0.000 pp | 0.01% +0.003 pp | USD0.95 +21.1% | 3 qtrs — |
| 63 | CIBC ASSET MANAGEMENT INC | 39.5K +39.5K (+100.0%) | 45.4K +45.4K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 64 | VIRTU FINANCIAL LLC | 36.5K +36.5K (+100.0%) | 42.0K +42.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.002 pp | USD1.15 +0.0% | 5 qtrs — |
| 65 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | 35.7K +— (+0.0%) | 41.1K -7.1K (-14.8%) | 0.01% +0.000 pp | 0.01% -0.001 pp | USD4.15 -72.3% | 25 qtrs — |
| 66 | PRUDENTIAL FINANCIAL INC | 33.8K -1.2K (-3.4%) | 38.9K -8.4K (-17.7%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.35 -14.8% | 2 qtrs — |
| 67 | ENTRYPOINT CAPITAL, LLC | 33.6K +33.6K (+100.0%) | 38.7K +38.7K (+100.0%) | 0.01% +0.009 pp | 0.02% +0.015 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 68 | VERMILLION & WHITE WEALTH MANAGEMENT GROUP, LLC | 32.0K -500.0 (-1.5%) | 36.8K -7.1K (-16.1%) | 0.01% 0.000 pp | 0.02% -0.005 pp | USD1.27 -9.4% | 8 qtrs — |
| 69 | PATHSTONE HOLDINGS, LLC | 30.0K -239.0 (-0.8%) | 34.5K -6.3K (-15.5%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.87 -38.5% | 9 qtrs — |
| 70 | TOWER RESEARCH CAPITAL LLC (TRC) | 29.1K +5.4K (+22.9%) | 33.5K +1.5K (+4.7%) | 0.01% +0.002 pp | 0.00% 0.000 pp | USD1.12 +2.7% | 34 qtrs — |
| 71 | PINNACLE ASSOCIATES LTD | 29.0K -21.8K (-42.9%) | 33.4K -35.2K (-51.4%) | 0.01% -0.006 pp | 0.00% -0.001 pp | USD5.48 -79.0% | 35 qtrs — |
| 72 | SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ | 26.7K +26.7K (+100.0%) | 30.6K +30.6K (+100.0%) | 0.01% +0.007 pp | 0.02% +0.020 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 73 | OPPENHEIMER & CO INC | 23.5K +— (+0.0%) | 27.0K -4.7K (-14.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.53 +117.0% | 4 qtrs — |
| 74 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 21.5K -1.9K (-8.1%) | 25.0K -7.0K (-21.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD0.79 +45.6% | 5 qtrs — |
| 75 | VICTORY CAPITAL MANAGEMENT INC | 21.2K +168.0 (+0.8%) | 24.4K -4.0K (-14.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.23 -48.4% | 21 qtrs — |
| 76 | INVERA WEALTH ADVISORS, LLC | 20.0K +— (+0.0%) | 23.0K -4.0K (-14.8%) | 0.01% +0.000 pp | 0.01% -0.002 pp | USD0.46 +150.0% | 4 qtrs — |
| 77 | TIAA TRUST, NATIONAL ASSOCIATION | 20.0K +— (+0.0%) | 23.0K -4.0K (-14.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.09 +5.5% | 10 qtrs — |
| 78 | BANK OF NEW YORK MELLON CORP | 19.1K +— (+0.0%) | 22.0K -3.8K (-14.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.64 -68.4% | 43 qtrs — |
| 79 | CREDIT AGRICOLE S A | 19.0K +19.0K (+100.0%) | 21.8K +21.8K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 80 | QUADRATURE CAPITAL LTD | 18.4K -209.8K (-91.9%) | 21.2K -288.0K (-93.2%) | 0.01% -0.058 pp | 0.00% -0.003 pp | USD1.35 -14.8% | 2 qtrs — |
| 81 | STONEX GROUP INC. | 16.2K +16.2K (+100.0%) | 18.7K +18.7K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.001 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 82 | SIMPLEX TRADING, LLC | 14.8K -58.5K (-79.9%) | 17.0K -81.0K (-82.7%) | 0.00% -0.016 pp | 0.00% +0.000 pp | USD0.82 +40.2% | 25 qtrs — |
| 83 | CETERA INVESTMENT ADVISERS | 14.2K -3.3K (-19.0%) | 16.3K -7.3K (-31.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.35 -14.8% | 2 qtrs — |
| 84 | LAZARD ASSET MANAGEMENT LLC | 14.1K +14.1K (+100.0%) | 16.2K +16.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 85 | CALLAN FAMILY OFFICE, LLC | 14.1K +14.1K (+100.0%) | 16.2K +16.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 86 | TRUIST FINANCIAL CORP | 14.0K +— (+0.0%) | 16.1K -2.8K (-14.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.15 +0.0% | 10 qtrs — |
| 87 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 13.5K -5.4K (-28.4%) | 15.4K -13.3K (-46.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD0.49 +134.7% | 4 qtrs — |
| 88 | SCHONFELD STRATEGIC ADVISORS LLC | 13.1K -812.5K (-98.4%) | 15.1K -1.1M (-98.6%) | 0.00% -0.224 pp | 0.00% -0.006 pp | USD0.96 +19.8% | 13 qtrs — |
| 89 | CWM, LLC | 13.2K -13.6K (-50.7%) | 15.0K -21.0K (-58.3%) | 0.00% -0.004 pp | 0.00% 0.000 pp | USD0.48 +139.6% | 5 qtrs — |
| 90 | HBK SORCE ADVISORY LLC | 11.8K +— (+0.0%) | 14.5K -3.5K (-19.6%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD0.95 +21.1% | 3 qtrs — |
| 91 | CHEMISTRY WEALTH MANAGEMENT LLC | 12.0K +— (+0.0%) | 13.8K -2.4K (-14.8%) | 0.00% +0.000 pp | 0.00% -0.001 pp | USD1.09 +5.5% | 10 qtrs — |
| 92 | CAPTRUST FINANCIAL ADVISORS | 11.7K -2.3K (-16.6%) | 13.5K -5.5K (-28.9%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.12 +2.7% | 12 qtrs — |
| 93 | FORTRESS WEALTH GROUP, LLC | 11.4K +11.4K (+100.0%) | 13.2K +13.2K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.005 pp | USD1.15 +0.0% | 1 qtrs NEW |
| 94 | PERENNIAL INVESTMENT ADVISORS, LLC | 11.0K +— (+0.0%) | 12.6K -2.2K (-14.8%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD0.95 +21.1% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 45 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 409.7K | 0.65% |
| 2 | State Street SPDR S&P Pharmaceuticals ETF XPH | 0.56% | 2.64M | 0.35% |
| 3 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.51% | 111.7K | 0.20% |
| 4 | iShares Micro-Cap ETF IWC | 0.12% | 1.85M | 0.60% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.12% | 27.1K | 1.22% |
| 6 | Texas Capital Texas Equity Index ETF TXS | 0.05% | 18.4K | 0.49% |
| 7 | iShares Russell 2000 Growth ETF IWO | 0.03% | 5.07M | 0.24% |
| 8 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.03% | 717.2K | 0.34% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.02% | 596.5K | 0.30% |
| 10 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 212.8K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
28
Sells
0
Shares acquired
31.67M
Shares disposed
—
Cash buys
8.00
Cash sales
—
Net activity
+31,670,824
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Swain Judith L | Director | A-Award | A | Restricted Stock Units | 35,714 | 0.00 | — | 35,714 | D | ↗ |
| 2026-05-01 | Sullivan Diane E. | Director | A-Award | A | Stock Option (Right to Buy) | 43,478 | 1.61 | 70.0K | 43,478 | D | ↗ |
| 2026-05-01 | SOBECKI CHRISTOPHER J | Director | A-Award | A | Restricted Stock Units | 35,714 | 0.00 | — | 35,714 | D | ↗ |
| 2026-05-01 | DEBBANE RAYMOND | Director | A-Award | A | Restricted Stock Units | 35,714 | 0.00 | — | 35,714 | D | ↗ |
| 2026-05-01 | Cheung Ivan | Director | A-Award | A | Restricted Stock Units | 35,714 | 0.00 | — | 35,714 | D | ↗ |
| 2026-05-01 | BARKER SAM L | Director | A-Award | A | Restricted Stock Units | 35,714 | 0.00 | — | 35,714 | D | ↗ |
| 2026-05-01 | Amouyal Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 43,478 | 1.61 | 70.0K | 43,478 | D | ↗ |
| 2026-02-28 | McDermott Wendy | Officer | M-Exempt | A | Common Stock | 144,393 | 0.00 | — | 346,052 | D | ↗ |
| 2026-02-28 | Martens Rachel Yap | Officer | M-Exempt | D | Restricted Stock Units | 67,090 | 0.00 | — | 134,180 | D | ↗ |
| 2026-02-28 | Granowitz Craig B | Officer | M-Exempt | A | Common Stock | 35,790 | 0.00 | — | 156,042 | D | ↗ |
| 2026-02-28 | Gopinathan Suma | Officer | M-Exempt | D | Restricted Stock Units | 14,000 | 0.00 | — | 0 | D | ↗ |
| 2026-02-28 | Exton Michael | Director / Officer | M-Exempt | D | Restricted Stock Units | 503,263 | 0.00 | — | 1,006,527 | D | ↗ |
| 2026-02-28 | DeFrancesco Lisa | Officer | M-Exempt | D | Restricted Stock Units | 128,190 | 0.00 | — | 256,380 | D | ↗ |
| 2026-02-28 | Crum Brian T | Officer | M-Exempt | D | Restricted Stock Units | 170,163 | 0.00 | — | 340,327 | D | ↗ |
| 2026-02-28 | Coiante Scott M | Officer | M-Exempt | D | Restricted Stock Units | 160,237 | 0.00 | — | 320,473 | D | ↗ |
| 2026-02-25 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 2,000 | 1.49 | 3.0K | 1,906,186 | D | ↗ |
| 2026-02-23 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 100,000 | 1.47 | 147.0K | 1,904,186 | D | ↗ |
| 2026-02-20 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 100,000 | 1.48 | 147.8K | 1,804,186 | D | ↗ |
| 2026-02-19 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 50,000 | 1.44 | 72.0K | 1,704,186 | D | ↗ |
| 2026-02-18 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 133,688 | 1.32 | 176.5K | 1,654,186 | D | ↗ |
| 2026-02-17 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 76,857 | 1.31 | 100.5K | 1,520,498 | D | ↗ |
| 2026-02-17 | Artal Participations S.a r.l. | Director / 10% Owner | A-Award | A | Series B Convertible Preferred Stock | 41,290 | 65.00 | 2.68M | 408,435 | I | ↗ |
| 2026-02-13 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 57,952 | 1.31 | 75.9K | 1,443,641 | D | ↗ |
| 2026-02-12 | McDermott Wendy | Officer | A-Award | A | Stock Option (Right to Buy) | 375,300 | 1.37 | 514.2K | 375,300 | D | ↗ |
| 2026-02-12 | Martens Rachel Yap | Officer | A-Award | A | Restricted Stock Units | 193,740 | 0.00 | — | 193,740 | D | ↗ |
| 2026-02-12 | Granowitz Craig B | Officer | A-Award | A | Stock Option (Right to Buy) | 519,920 | 1.37 | 712.3K | 519,920 | D | ↗ |
| 2026-02-12 | Gopinathan Suma | Officer | A-Award | A | Restricted Stock Units | 238,450 | 0.00 | — | 238,450 | D | ↗ |
| 2026-02-12 | Exton Michael | Director / Officer | A-Award | A | Restricted Stock Units | 862,440 | 0.00 | — | 862,440 | D | ↗ |
| 2026-02-12 | DeFrancesco Lisa | Officer | A-Award | A | Restricted Stock Units | 257,530 | 0.00 | — | 257,530 | D | ↗ |
| 2026-02-12 | Crum Brian T | Officer | A-Award | A | Stock Option (Right to Buy) | 449,560 | 1.37 | 615.9K | 449,560 | D | ↗ |
| 2026-02-12 | Coiante Scott M | Officer | A-Award | A | Restricted Stock Units | 272,680 | 0.00 | — | 272,680 | D | ↗ |
| 2026-02-02 | Invus Global Management, LLC | Director / 10% Owner | A-Award | A | Common Stock | 3,846,154 | 1.30 | 5.00M | 7,362,368 | I | ↗ |
| 2026-02-02 | Avicenna Life Sci Master Fund LP | Director / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,538,462 | I | ↗ |
| 2025-06-03 | Swain Judith L | Director | A-Award | A | Restricted Stock Units | 89,312 | 0.00 | — | 89,312 | D | ↗ |
| 2025-06-03 | Sullivan Diane E. | Director | A-Award | A | Stock Option (Right to Buy) | 103,806 | 0.62 | 64.5K | 103,806 | D | ↗ |
| 2025-06-03 | SOBECKI CHRISTOPHER J | Director | A-Award | A | Stock Option (Right to Buy) | 103,806 | 0.62 | 64.5K | 103,806 | D | ↗ |
| 2025-06-03 | DEBBANE RAYMOND | Director | A-Award | A | Stock Option (Right to Buy) | 103,806 | 0.62 | 64.5K | 103,806 | D | ↗ |
| 2025-06-03 | Cheung Ivan | Director | A-Award | A | Restricted Stock Units | 89,312 | 0.00 | — | 89,312 | D | ↗ |
| 2025-06-03 | BARKER SAM L | Director | A-Award | A | Stock Option (Right to Buy) | 103,806 | 0.62 | 64.5K | 103,806 | D | ↗ |
| 2025-06-03 | Amouyal Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 103,806 | 0.62 | 64.5K | 103,806 | D | ↗ |
| 2025-06-01 | Martens Rachel Yap | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-01 | Gopinathan Suma | Officer | — | — | Stock Option (Right to Buy) | 28,000 | 2.43 | 68.0K | 0 | D | ↗ |
| 2025-05-13 | Swain Judith L | Director | M-Exempt | D | Restricted Stock Units | 36,810 | 0.00 | — | 0 | D | ↗ |
| 2025-05-13 | Sullivan Diane E. | Director | M-Exempt | A | Common Stock | 36,810 | 0.00 | — | 36,810 | D | ↗ |
| 2025-05-13 | SOBECKI CHRISTOPHER J | Director | M-Exempt | D | Restricted Stock Units | 36,810 | 0.00 | — | 0 | D | ↗ |
| 2025-05-13 | DEBBANE RAYMOND | Director | M-Exempt | A | Common Stock | 36,810 | 0.00 | — | 1,385,689 | D | ↗ |
| 2025-05-13 | BARKER SAM L | Director | M-Exempt | D | Restricted Stock Units | 36,810 | 0.00 | — | 0 | D | ↗ |
| 2025-05-13 | Amouyal Philippe | Director | M-Exempt | A | Common Stock | 36,810 | 0.00 | — | 285,174 | D | ↗ |
| 2025-02-28 | McDermott Wendy | Officer | F-InKind | D | Common Stock | 30,004 | 0.67 | 20.1K | 121,646 | D | ↗ |
| 2025-02-28 | MAIN ALAN J | Officer | M-Exempt | D | Restricted Stock Units | 25,667 | 0.00 | — | 0 | D | ↗ |
| 2025-02-28 | Granowitz Craig B | Officer | M-Exempt | A | Common Stock | 74,227 | 0.00 | — | 185,560 | D | ↗ |
| 2025-02-28 | DeFrancesco Lisa | Officer | M-Exempt | A | Common Stock | 24,673 | 0.00 | — | 24,673 | D | ↗ |
| 2025-02-28 | Crum Brian T | Officer | M-Exempt | A | Common Stock | 69,387 | 0.00 | — | 306,437 | D | ↗ |
| 2025-02-28 | Alexander Kristen | Officer | M-Exempt | A | Common Stock | 19,887 | 0.00 | — | 94,230 | D | ↗ |
| 2025-02-13 | McDermott Wendy | Officer | A-Award | A | Restricted Stock Units | 433,180 | 0.00 | — | 433,180 | D | ↗ |
| 2025-02-13 | MAIN ALAN J | Officer | A-Award | A | Restricted Stock Units | 502,060 | 0.00 | — | 502,060 | D | ↗ |
| 2025-02-13 | Granowitz Craig B | Officer | A-Award | A | Restricted Stock Units | 606,780 | 0.00 | — | 606,780 | D | ↗ |
| 2025-02-13 | Exton Michael | Director / Officer | A-Award | A | Restricted Stock Units | 1,509,790 | 0.00 | — | 1,509,790 | D | ↗ |
| 2025-02-13 | DeFrancesco Lisa | Officer | A-Award | A | Restricted Stock Units | 384,570 | 0.00 | — | 384,570 | D | ↗ |
| 2025-02-13 | Crum Brian T | Officer | A-Award | A | Restricted Stock Units | 510,490 | 0.00 | — | 510,490 | D | ↗ |
| 2025-02-13 | Corrigan Brian | Officer | A-Award | A | Restricted Stock Units | 448,660 | 0.00 | — | 448,660 | D | ↗ |
| 2025-02-13 | Coiante Scott M | Officer | A-Award | A | Restricted Stock Units | 480,710 | 0.00 | — | 480,710 | D | ↗ |
| 2025-02-13 | Alexander Kristen | Officer | A-Award | A | Stock Option (Right to Buy) | 185,540 | 0.70 | 129.0K | 185,540 | D | ↗ |
| 2025-01-02 | Coiante Scott M | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 0.74 | 169.9K | 230,000 | D | ↗ |
| 2024-12-05 | Artal Participations S.a r.l. | Director / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 136,180,481 | D | ↗ |
| 2024-12-02 | Cheung Ivan | Director | A-Award | A | Stock Option (Right to Buy) | 186,685 | 0.80 | 150.0K | 186,685 | D | ↗ |
| 2024-10-02 | DeFrancesco Lisa | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-08-12 | Corrigan Brian | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.60 | 320.0K | 200,000 | — | ↗ |
| 2024-07-25 | Siren, L.L.C. | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 35,402,689 | — | ↗ |
| 2024-07-08 | WADE JEFFREY L | Officer | A-Award | A | Stock Option (Right to Buy) | 307,000 | 1.67 | 512.7K | 307,000 | — | ↗ |
| 2024-07-08 | Exton Michael | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,675,000 | 1.67 | 2.80M | 1,675,000 | — | ↗ |
| 2024-05-13 | Swain Judith L | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-13 | Sullivan Diane E. | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-13 | SOBECKI CHRISTOPHER J | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-13 | LEFKOWITZ ROBERT J MD | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-13 | DEBBANE RAYMOND | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-13 | BARKER SAM L | Director | A-Award | A | Stock Option (Right to Buy) | 44,906 | 1.79 | 80.4K | 44,906 | — | ↗ |
| 2024-05-13 | Amouyal Philippe | Director | A-Award | A | Restricted Stock Units | 36,810 | 0.00 | — | 36,810 | — | ↗ |
| 2024-05-10 | Artal International S.C.A. | Director / 10% Owner | M-Exempt | D | Series A Convertible Preferred Stock | 1,150,922 | 0.00 | — | 0 | — | ↗ |
| 2024-04-28 | Swain Judith L | Director | M-Exempt | D | Restricted Stock Units | 8,032 | 0.00 | — | 0 | — | ↗ |
| 2024-04-28 | SOBECKI CHRISTOPHER J | Director | M-Exempt | A | Common Stock | 8,032 | 0.00 | — | 167,055 | — | ↗ |
| 2024-04-28 | LEFKOWITZ ROBERT J MD | Director | M-Exempt | A | Common Stock | 8,032 | 0.00 | — | 48,364 | — | ↗ |
| 2024-04-28 | DEBBANE RAYMOND | Director | M-Exempt | A | Common Stock | 8,032 | 0.00 | — | 1,348,879 | — | ↗ |
| 2024-04-28 | BARKER SAM L | Director | M-Exempt | D | Restricted Stock Units | 8,032 | 0.00 | — | 0 | — | ↗ |
| 2024-04-28 | Amouyal Philippe | Director | M-Exempt | D | Restricted Stock Units | 8,032 | 0.00 | — | 0 | — | ↗ |
| 2024-03-13 | Artal International S.C.A. | Director / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 1,150,922 | 108.50 | 124.88M | 1,150,922 | — | ↗ |
| 2024-02-28 | WADE JEFFREY L | Officer | M-Exempt | A | Common Stock | 11,177 | 0.00 | — | 275,518 | — | ↗ |
| 2024-02-28 | McDermott Wendy | Officer | M-Exempt | A | Common Stock | 27,697 | 0.00 | — | 75,119 | — | ↗ |
| 2024-02-28 | MAIN ALAN J | Officer | M-Exempt | D | Restricted Stock Units | 8,977 | 0.00 | — | 0 | — | ↗ |
| 2024-02-28 | Kassler-Taub Kenneth B. | Officer | M-Exempt | D | Restricted Stock Units | 32,757 | 0.00 | — | 65,513 | — | ↗ |
| 2024-02-28 | Granowitz Craig B | Officer | M-Exempt | A | Common Stock | 35,790 | 0.00 | — | 78,891 | — | ↗ |
| 2024-02-28 | Crum Brian T | Officer | F-InKind | D | Common Stock | 25,604 | 2.62 | 67.1K | 177,497 | — | ↗ |
| 2024-02-28 | COATS LONNEL | Director / Officer | M-Exempt | A | Common Stock | 120,383 | 0.00 | — | 1,159,439 | — | ↗ |
| 2024-02-28 | Alexander Kristen | Officer | M-Exempt | A | Common Stock | 15,927 | 0.00 | — | 59,593 | — | ↗ |
| 2024-02-08 | WADE JEFFREY L | Officer | A-Award | A | Stock Option (Right to Buy) | 314,320 | 2.15 | 675.8K | 314,320 | — | ↗ |
| 2024-02-08 | McDermott Wendy | Officer | A-Award | A | Restricted Stock Units | 156,950 | 0.00 | — | 156,950 | — | ↗ |
| 2024-02-08 | MAIN ALAN J | Officer | A-Award | A | Restricted Stock Units | 204,730 | 0.00 | — | 204,730 | — | ↗ |
| 2024-02-08 | Kassler-Taub Kenneth B. | Officer | A-Award | A | Stock Option (Right to Buy) | 203,810 | 2.15 | 438.2K | 203,810 | — | ↗ |
| 2024-02-08 | Granowitz Craig B | Officer | A-Award | A | Restricted Stock Units | 222,680 | 0.00 | — | 222,680 | — | ↗ |
| 2024-02-08 | Garner Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 227,130 | 2.15 | 488.3K | 227,130 | — | ↗ |
| 2024-02-08 | Crum Brian T | Officer | A-Award | A | Restricted Stock Units | 208,160 | 0.00 | — | 208,160 | — | ↗ |
| 2024-02-08 | COATS LONNEL | Director / Officer | A-Award | A | Restricted Stock Units | 770,420 | 0.00 | — | 770,420 | — | ↗ |
| 2024-02-08 | Alexander Kristen | Officer | A-Award | A | Stock Option (Right to Buy) | 59,660 | 2.15 | 128.3K | 59,660 | — | ↗ |
| 2023-11-16 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 90,000 | 1.05 | 94.8K | 914,359 | — | ↗ |
| 2023-11-10 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.01 | 10.1K | 824,359 | — | ↗ |
| 2023-10-12 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 148,820 | 1.03 | 153.8K | 1,340,847 | — | ↗ |
| 2023-10-11 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 342,874 | 1.08 | 370.8K | 1,192,027 | — | ↗ |
| 2023-10-10 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 508,306 | 1.14 | 579.4K | 849,153 | — | ↗ |
| 2023-10-09 | Garner Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 248,923 | 1.08 | 268.8K | 248,923 | — | ↗ |
| 2023-09-14 | WADE JEFFREY L | Officer | P-Purchase | A | Common Stock | 10,000 | 1.38 | 13.8K | 264,341 | — | ↗ |
| 2023-08-04 | McDermott Wendy | Officer | P-Purchase | A | Common Stock | 6,000 | 1.84 | 11.0K | 28,478 | — | ↗ |
| 2023-07-27 | Sullivan Diane E. | Director | A-Award | A | Stock Option (Right to Buy) | 96,515 | 1.94 | 187.2K | 96,515 | — | ↗ |
| 2023-06-29 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.16 | 21.6K | 814,359 | — | ↗ |
| 2023-06-26 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.18 | 21.8K | 804,359 | — | ↗ |
| 2023-06-23 | McDermott Wendy | Officer | P-Purchase | A | Common Stock | 10,000 | 2.43 | 24.3K | 22,478 | — | ↗ |
| 2023-06-23 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.50 | 25.0K | 794,359 | — | ↗ |
| 2023-06-22 | COATS LONNEL | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 2.31 | 92.4K | 784,359 | — | ↗ |
| 2023-06-20 | WADE JEFFREY L | Officer | P-Purchase | A | Common Stock | 2,000 | 2.33 | 4.7K | 254,341 | — | ↗ |
| 2023-06-05 | Artal International S.C.A. | Director / 10% Owner | P-Purchase | A | Common Stock | 27,775,050 | 2.60 | 72.22M | 78,634,381 | — | ↗ |
| 2023-05-21 | Swain Judith L | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | SOBECKI CHRISTOPHER J | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | Palantoni Frank | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | NIES ALAN S | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | LEFKOWITZ ROBERT J MD | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | DEBBANE RAYMOND | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | BARKER SAM L | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-05-21 | Amouyal Philippe | Director | M-Exempt | D | Restricted Stock Units | 9,302 | 0.00 | — | 0 | — | ↗ |
| 2023-04-28 | Swain Judith L | Director | A-Award | A | Restricted Stock Units | 8,032 | 0.00 | — | 8,032 | — | ↗ |
| 2023-04-28 | SOBECKI CHRISTOPHER J | Director | A-Award | A | Restricted Stock Units | 8,032 | 0.00 | — | 8,032 | — | ↗ |
| 2023-04-28 | Palantoni Frank | Director | A-Award | A | Restricted Stock Units | 8,032 | 0.00 | — | 8,032 | — | ↗ |
| 2023-04-28 | NIES ALAN S | Director | A-Award | A | Restricted Stock Units | 8,032 | 0.00 | — | 8,032 | — | ↗ |
| 2023-04-28 | LEFKOWITZ ROBERT J MD | Director | A-Award | A | Stock Option (Right to Buy) | 12,658 | 2.36 | 29.9K | 12,658 | — | ↗ |
| 2023-04-28 | DEBBANE RAYMOND | Director | A-Award | A | Stock Option (Right to Buy) | 12,658 | 2.36 | 29.9K | 12,658 | — | ↗ |
| 2023-04-28 | BARKER SAM L | Director | A-Award | A | Restricted Stock Units | 8,032 | 0.00 | — | 8,032 | — | ↗ |
| 2023-04-28 | Amouyal Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 12,658 | 2.36 | 29.9K | 12,658 | — | ↗ |
| 2023-02-28 | WADE JEFFREY L | Officer | M-Exempt | A | Common Stock | 37,273 | 0.00 | — | 272,596 | — | ↗ |
| 2023-02-28 | Seth Kiernan | Officer | M-Exempt | A | Common Stock | 14,833 | 0.00 | — | 36,700 | — | ↗ |
| 2023-02-28 | McDermott Wendy | Officer | F-InKind | D | Common Stock | 6,465 | 2.17 | 14.0K | 12,478 | — | ↗ |
| 2023-02-28 | MAIN ALAN J | Officer | M-Exempt | A | Common Stock | 25,667 | 0.00 | — | 233,532 | — | ↗ |
| 2023-02-28 | Kassler-Taub Kenneth B. | Officer | M-Exempt | D | Restricted Stock Units | 18,243 | 0.00 | — | 0 | — | ↗ |
| 2023-02-28 | Granowitz Craig B | Officer | M-Exempt | D | Restricted Stock Units | 27,917 | 0.00 | — | 55,833 | — | ↗ |
| 2023-02-28 | Crum Brian T | Officer | M-Exempt | A | Common Stock | 26,097 | 0.00 | — | 155,335 | — | ↗ |
| 2023-02-28 | COATS LONNEL | Director / Officer | M-Exempt | D | Restricted Stock Units | 84,630 | 0.00 | — | 0 | — | ↗ |
| 2023-02-28 | Alexander Kristen | Officer | F-InKind | D | Common Stock | 5,330 | 2.17 | 11.6K | 30,350 | — | ↗ |
| 2023-02-09 | WADE JEFFREY L | Officer | A-Award | A | Restricted Stock Units | 147,340 | 0.00 | — | 147,340 | — | ↗ |
| 2023-02-09 | Seth Kiernan | Officer | A-Award | A | Restricted Stock Units | 93,370 | 0.00 | — | 93,370 | — | ↗ |
| 2023-02-09 | McDermott Wendy | Officer | A-Award | A | Restricted Stock Units | 83,090 | 0.00 | — | 83,090 | — | ↗ |
| 2023-02-09 | MAIN ALAN J | Officer | A-Award | A | Restricted Stock Units | 98,710 | 0.00 | — | 98,710 | — | ↗ |
| 2023-02-09 | Kassler-Taub Kenneth B. | Officer | A-Award | A | Restricted Stock Units | 98,270 | 0.00 | — | 98,270 | — | ↗ |
| 2023-02-09 | Granowitz Craig B | Officer | A-Award | A | Restricted Stock Units | 107,370 | 0.00 | — | 107,370 | — | ↗ |
| 2023-02-09 | Crum Brian T | Officer | A-Award | A | Restricted Stock Units | 100,370 | 0.00 | — | 100,370 | — | ↗ |
| 2023-02-09 | COATS LONNEL | Director / Officer | A-Award | A | Restricted Stock Units | 361,150 | 0.00 | — | 361,150 | — | ↗ |
| 2023-02-09 | Alexander Kristen | Officer | A-Award | A | Restricted Stock Units | 47,780 | 0.00 | — | 47,780 | — | ↗ |
| 2022-08-05 | Invus US Partners LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 147,390 | 2.50 | 368.5K | 5,451,204 | — | ↗ |
| 2022-08-05 | Invus Advisors, L.L.C. | Director | P-Purchase | A | Common Stock | 2,426,070 | 2.50 | 6.07M | 50,859,331 | — | ↗ |
| 2022-08-05 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 147,390 | 2.50 | 368.5K | 5,451,204 | — | ↗ |
| 2022-08-05 | Artal International S.C.A. | Director / 10% Owner | P-Purchase | A | Common Stock | 2,426,070 | 2.50 | 6.07M | 50,859,331 | — | ↗ |
| 2022-08-01 | Invus US Partners LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 982,600 | 2.50 | 2.46M | 5,303,814 | — | ↗ |
| 2022-08-01 | Invus Advisors, L.L.C. | Director | P-Purchase | A | Common Stock | 16,173,800 | 2.50 | 40.43M | 48,433,261 | — | ↗ |
| 2022-08-01 | DEBBANE RAYMOND | Director | P-Purchase | A | Common Stock | 982,600 | 2.50 | 2.46M | 5,303,814 | — | ↗ |
| 2022-08-01 | Artal International S.C.A. | Director / 10% Owner | P-Purchase | A | Common Stock | 16,173,800 | 2.50 | 40.43M | 48,433,261 | — | ↗ |
| 2022-05-21 | Swain Judith L | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | SOBECKI CHRISTOPHER J | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | Palantoni Frank | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | NIES ALAN S | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | LEFKOWITZ ROBERT J MD | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | DEBBANE RAYMOND | Director | A-Award | A | Stock Option (Right to Buy) | 14,402 | 0.00 | — | 14,402 | — | ↗ |
| 2022-05-21 | BARKER SAM L | Director | A-Award | A | Restricted Stock Units | 9,302 | 0.00 | — | 9,302 | — | ↗ |
| 2022-05-21 | Amouyal Philippe | Director | A-Award | A | Stock Option (Right to Buy) | 14,402 | 0.00 | — | 14,402 | — | ↗ |
| 2022-04-30 | Swain Judith L | Director | M-Exempt | D | Restricted Stock Units | 4,024 | 0.00 | — | 0 | — | ↗ |
| 2022-04-30 | SOBECKI CHRISTOPHER J | Director | M-Exempt | A | Common Stock | 4,024 | 0.00 | — | 149,721 | — | ↗ |
| 2022-04-30 | Palantoni Frank | Director | M-Exempt | D | Restricted Stock Units | 4,024 | 0.00 | — | 0 | — | ↗ |
| 2022-04-30 | NIES ALAN S | Director | M-Exempt | A | Common Stock | 4,024 | 0.00 | — | 31,744 | — | ↗ |
| 2022-04-30 | LEFKOWITZ ROBERT J MD | Director | M-Exempt | D | Restricted Stock Units | 4,024 | 0.00 | — | 0 | — | ↗ |
| 2022-04-30 | DEBBANE RAYMOND | Director | M-Exempt | A | Common Stock | 4,024 | 0.00 | — | 331,545 | — | ↗ |
| 2022-04-30 | BARKER SAM L | Director | M-Exempt | A | Common Stock | 4,024 | 0.00 | — | 70,315 | — | ↗ |
| 2022-04-30 | Amouyal Philippe | Director | M-Exempt | D | Restricted Stock Units | 4,024 | 0.00 | — | 0 | — | ↗ |
| 2022-02-28 | WADE JEFFREY L | Officer | F-InKind | D | Common Stock | 25,773 | 2.85 | 73.5K | 193,680 | — | ↗ |
| 2022-02-28 | Seth Kiernan | Officer | M-Exempt | A | Common Stock | 10,007 | 0.00 | — | 10,007 | — | ↗ |
| 2022-02-28 | MAIN ALAN J | Officer | M-Exempt | D | Restricted Stock Units | 23,300 | 0.00 | — | 23,300 | — | ↗ |
| 2022-02-28 | Kassler-Taub Kenneth B. | Officer | M-Exempt | D | Restricted Stock Units | 11,297 | 0.00 | — | 0 | — | ↗ |
| 2022-02-28 | Crum Brian T | Officer | M-Exempt | A | Common Stock | 8,750 | 0.00 | — | 114,517 | — | ↗ |
| 2022-02-28 | COATS LONNEL | Director / Officer | M-Exempt | A | Common Stock | 33,333 | 0.00 | — | 634,056 | — | ↗ |
| 2022-02-28 | Alexander Kristen | Officer | M-Exempt | A | Common Stock | 2,700 | 0.00 | — | 20,300 | — | ↗ |
| 2022-02-10 | WADE JEFFREY L | Officer | A-Award | A | Restricted Stock Units | 111,820 | 0.00 | — | 111,820 | — | ↗ |
| 2022-02-10 | Seth Kiernan | Officer | A-Award | A | Restricted Stock Units | 68,890 | 0.00 | — | 68,890 | — | ↗ |
| 2022-02-10 | McDermott Wendy | Officer | A-Award | A | Stock Option (Right to Buy) | 170,500 | 3.20 | 545.6K | 170,500 | — | ↗ |
| 2022-02-10 | MAIN ALAN J | Officer | A-Award | A | Restricted Stock Units | 77,000 | 0.00 | — | 77,000 | — | ↗ |
| 2022-02-10 | Kassler-Taub Kenneth B. | Officer | A-Award | A | Stock Option (Right to Buy) | 248,010 | 3.20 | 793.6K | 248,010 | — | ↗ |
| 2022-02-10 | Granowitz Craig B | Officer | A-Award | A | Restricted Stock Units | 83,750 | 0.00 | — | 83,750 | — | ↗ |
| 2022-02-10 | Crum Brian T | Officer | A-Award | A | Restricted Stock Units | 78,290 | 0.00 | — | 78,290 | — | ↗ |
| 2022-02-10 | COATS LONNEL | Director / Officer | A-Award | A | Restricted Stock Units | 274,090 | 0.00 | — | 274,090 | — | ↗ |
| 2022-02-10 | Alexander Kristen | Officer | A-Award | A | Restricted Stock Units | 31,850 | 0.00 | — | 31,850 | — | ↗ |
| 2022-01-03 | McDermott Wendy | Officer | A-Award | A | Stock Option (Right to Buy) | 85,185 | 3.94 | 335.6K | 85,185 | — | ↗ |
| 2021-12-31 | WADE JEFFREY L | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | SOBECKI CHRISTOPHER J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Seth Kiernan | Officer | — | D | Stock Option (Right to Buy) | 13,500 | 14.44 | 194.9K | 0 | — | ↗ |
| 2021-10-01 | Kassler-Taub Kenneth B. | Officer | — | D | Stock Option (Right to Buy) | 23,720 | 9.79 | 232.2K | 0 | — | ↗ |
| 2021-09-25 | Alexander Kristen | Officer | — | D | Stock Option (Right to Buy) | 9,184 | 16.40 | 150.6K | 0 | — | ↗ |
| 2021-08-02 | Granowitz Craig B | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 3.54 | 885.0K | 250,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-474.9K
Shares Outstanding
423.68M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael S. Exton, Ph.D. Chief Executive Officer and Director | 650.6K | 483.8K | 1.05M | 1.36M | — | 15.0K | 3.55M | 67.66% | ↗ |
| 2 | 2024 | Sciences Lonnel Coats Former Chief Executive Officer and Director | 438.8K | — | 1.66M | 1.36M | — | 59.5K | 3.51M | 85.82% | ↗ |
| 3 | 2024 | Michael S. Exton, Ph.D. Chief Executive Officer and Director | 303.7K | 222.6K | — | 2.31M | — | 493.00 | 2.84M | 81.42% | ↗ |
| 4 | 2024 | Jeffrey L. Wade Former President and Chief Financial Officer | 485.5K | — | 675.8K | 977.2K | — | 425.7K | 2.56M | 64.46% | ↗ |
| 5 | 2024 | Thomas A. Garner Former Senior Vice President and Chief Commercial Officer | 471.0K | — | 488.3K | 400.4K | — | 627.7K | 1.99M | 44.72% | ↗ |
| 6 | 2024 | Craig B. Granowitz, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 501.7K | 199.4K | 478.8K | 392.5K | — | 16.0K | 1.59M | 54.85% | ↗ |
| 7 | 2024 | Brian T. Crum Senior Vice President and General Counsel | 473.5K | 125.4K | 447.5K | 366.9K | — | 17.2K | 1.43M | 56.93% | ↗ |
| 8 | 2024 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 457.8K | 123.4K | 440.2K | 360.9K | — | 14.3K | 1.40M | 57.36% | ↗ |
| 9 | 2024 | Kristen L. Alexander Vice President, Finance and Accounting | 295.6K | 67.4K | 128.3K | 105.2K | — | 16.8K | 613.2K | 38.07% | ↗ |
| 10 | 2023 | Lonnel Coats Chief Executive Officer and Director | 740.8K | 386.2K | 877.6K | 2.09M | — | 15.2K | 4.11M | 72.21% | ↗ |
| 11 | 2023 | Sciences Lonnel Coats Former Chief Executive Officer and Director | 740.8K | 386.2K | 877.6K | 2.09M | — | 15.2K | 4.11M | 72.21% | ↗ |
| 12 | 2023 | Jeffrey L. Wade President and Chief Financial Officer | 535.7K | 200.1K | 358.0K | 852.8K | — | 16.2K | 1.96M | 61.69% | ↗ |
| 13 | 2023 | Jeffrey L. Wade Former President and Chief Financial Officer | 535.7K | 200.1K | 358.0K | 852.8K | — | 16.2K | 1.96M | 61.69% | ↗ |
| 14 | 2023 | Craig B. Granowitz, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 487.6K | 149.7K | 260.9K | 621.4K | — | 15.2K | 1.53M | 57.49% | ↗ |
| 15 | 2023 | Brian T. Crum Senior Vice President and General Counsel | 457.9K | 122.4K | 243.9K | 580.9K | — | 16.1K | 1.42M | 58.03% | ↗ |
| 16 | 2023 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 442.8K | 120.4K | 239.9K | 571.3K | — | 13.8K | 1.39M | 58.44% | ↗ |
| 17 | 2023 | Thomas A. Garner Former Senior Vice President and Chief Commercial Officer | 214.6K | 276.1K | — | 219.0K | — | 568.00 | 710.3K | 30.83% | ↗ |
| 18 | 2023 | Kristen L. Alexander Vice President, Finance and Accounting | 285.4K | 67.5K | 116.1K | 138.3K | — | 15.8K | 623.0K | 40.83% | ↗ |
| 19 | 2022 | Lonnel Coats Chief Executive Officer and Director | 709.6K | 502.0K | 877.1K | 2.07M | — | 13.2K | 4.17M | 70.63% | ↗ |
| 20 | 2022 | Sciences Lonnel Coats Former Chief Executive Officer and Director | 709.6K | 502.0K | 877.1K | 2.07M | — | 13.2K | 4.17M | 70.63% | ↗ |
| 21 | 2022 | Jeffrey L. Wade Former President and Chief Financial Officer | 513.4K | 260.1K | 357.8K | 843.7K | — | 15.2K | 1.99M | 60.37% | ↗ |
| 22 | 2022 | Jeffrey L. Wade President and Chief Financial Officer | 513.4K | 260.1K | 357.8K | 843.7K | — | 15.2K | 1.99M | 60.37% | ↗ |
| 23 | 2022 | Craig B. Granowitz, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 467.5K | 189.5K | 268.0K | 631.9K | — | 14.2K | 1.57M | 57.28% | ↗ |
| 24 | 2022 | Kenneth B. Kassler-Taub, M.D. Senior Vice President, Regulatory and Quality | 424.1K | 151.8K | 264.5K | 623.7K | — | 12.8K | 1.48M | 60.14% | ↗ |
| 25 | 2022 | Brian T. Crum Senior Vice President and General Counsel | 439.0K | 155.0K | 250.5K | 590.7K | — | 15.1K | 1.45M | 58.00% | ↗ |
| 26 | 2022 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 426.2K | 152.5K | 246.4K | 580.9K | — | 12.8K | 1.42M | 58.31% | ↗ |
| 27 | 2022 | Kristen L. Alexander Vice President, Finance and Accounting | 269.9K | 82.0K | 101.9K | 120.2K | — | 14.8K | 588.8K | 37.72% | ↗ |
| 28 | 2021 | Lonnel Coats Chief Executive Officer and Director | 688.8K | 438.6K | 838.0K | 1.95M | — | 12.6K | 3.92M | 70.95% | ↗ |
| 29 | 2021 | Jeffrey L. Wade President and Chief Financial Officer | 476.3K | 227.3K | 281.0K | 652.6K | — | 14.6K | 1.65M | 56.52% | ↗ |
| 30 | 2021 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 414.0K | 148.0K | 225.7K | 524.0K | — | 12.2K | 1.32M | 56.63% | ↗ |
| 31 | 2021 | Brian T. Crum Senior Vice President and General Counsel | 407.6K | 135.5K | 220.0K | 510.9K | — | 14.4K | 1.29M | 56.73% | ↗ |
| 32 | 2021 | Craig B. Granowitz, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 188.3K | 73.2K | — | 686.4K | — | 646.00 | 948.5K | 72.36% | ↗ |
| 33 | 2021 | Kenneth B. Kassler-Taub, M.D. Senior Vice President, Regulatory and Quality | 392.6K | 152.8K | 178.2K | 206.9K | — | 12.1K | 942.6K | 40.85% | ↗ |
| 34 | 2020 | Lonnel Coats Chief Executive Officer and Director | 668.6K | 473.2K | 840.4K | 1.87M | — | 12.4K | 3.86M | 70.10% | ↗ |
| 35 | 2020 | Lonnel Coats President, Chief Executive Officer and Director | 668.6K | 473.2K | 840.4K | 1.87M | — | 12.4K | 3.86M | 70.10% | ↗ |
| 36 | 2020 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical Officer | 317.1K | — | 272.8K | 605.7K | — | 667.3K | 1.86M | 47.16% | ↗ |
| 37 | 2020 | Jeffrey L. Wade President and Chief Financial Officer | 456.4K | 185.0K | 302.5K | 671.8K | — | 13.8K | 1.63M | 59.79% | ↗ |
| 38 | 2020 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 456.4K | 185.0K | 302.5K | 671.8K | — | 13.8K | 1.63M | 59.79% | ↗ |
| 39 | 2020 | Sciences Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 483.2K | 196.8K | 284.9K | 632.6K | — | 12.4K | 1.61M | 56.99% | ↗ |
| 40 | 2020 | Alexander A. Santini Former Executive Vice President and Chief Commercial Officer | 315.1K | — | 233.6K | 518.6K | — | 286.8K | 1.35M | 55.55% | ↗ |
| 41 | 2020 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 403.8K | 144.4K | 231.4K | 513.8K | — | 11.9K | 1.31M | 57.08% | ↗ |
| 42 | 2020 | Brian T. Crum Senior Vice President and General Counsel | 387.7K | 137.0K | 208.8K | 463.7K | — | 12.2K | 1.21M | 55.62% | ↗ |
| 43 | 2020 | Brian T. Crum Vice President and General Counsel | 387.7K | 137.0K | 208.8K | 463.7K | — | 12.2K | 1.21M | 55.62% | ↗ |
| 44 | 2020 | Kenneth B. Kassler-Taub, M.D. Senior Vice President, Regulatory and Quality | 375.1K | 116.2K | 181.2K | 201.3K | — | 12.0K | 704.6K | 54.28% | ↗ |
| 45 | 2019 | Lonnel Coats President, Chief Executive Officer and Director | 649.2K | 459.4K | 1.23M | 1.52M | — | 12.2K | 3.87M | 71.04% | ↗ |
| 46 | 2019 | Lonnel Coats Chief Executive Officer and Director | 649.2K | 459.4K | 1.23M | 1.52M | — | 12.2K | 3.87M | 71.04% | ↗ |
| 47 | 2019 | Sciences Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 475.0K | 192.4K | 486.8K | 509.6K | — | 12.2K | 1.68M | 59.45% | ↗ |
| 48 | 2019 | Jeffrey L. Wade President and Chief Financial Officer | 444.4K | 181.8K | 491.5K | 484.5K | — | 12.1K | 1.61M | 60.46% | ↗ |
| 49 | 2019 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 444.4K | 181.8K | 491.5K | 484.5K | — | 12.1K | 1.61M | 60.46% | ↗ |
| 50 | 2019 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical Officer | 410.5K | 148.4K | 438.2K | 449.4K | — | 12.0K | 1.46M | 60.86% | ↗ |
| 51 | 2019 | Alexander A. Santini Former Executive Vice President and Chief Commercial Officer | 409.5K | 166.8K | 428.8K | 437.8K | — | 12.0K | 1.45M | 59.56% | ↗ |
| 52 | 2019 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 393.3K | 140.5K | 421.3K | 428.6K | — | 11.7K | 1.40M | 60.91% | ↗ |
| 53 | 2019 | Brian T. Crum Vice President and General Counsel | 369.3K | 133.1K | 246.8K | 171.7K | — | 12.0K | 932.9K | 44.87% | ↗ |
| 54 | 2019 | Brian T. Crum Senior Vice President and General Counsel | 369.3K | 133.1K | 246.8K | 171.7K | — | 12.0K | 932.9K | 44.87% | ↗ |
| 55 | 2018 | Lonnel Coats President, Chief Executive Officer and Director | 634.2K | 402.4K | 690.6K | 1.38M | — | 12.0K | 3.12M | 66.43% | ↗ |
| 56 | 2018 | Sciences Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 464.6K | 160.9K | 285.7K | 541.8K | — | 12.0K | 1.46M | 56.48% | ↗ |
| 57 | 2018 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 464.6K | 160.9K | 285.7K | 541.8K | — | 12.0K | 1.46M | 56.48% | ↗ |
| 58 | 2018 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 436.6K | 158.5K | 280.6K | 520.4K | — | 11.9K | 1.41M | 56.89% | ↗ |
| 59 | 2018 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical Officer | 401.5K | 121.6K | 251.7K | 473.2K | — | 11.8K | 1.26M | 57.54% | ↗ |
| 60 | 2018 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 401.5K | 121.6K | 251.7K | 473.2K | — | 11.8K | 1.26M | 57.54% | ↗ |
| 61 | 2018 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 399.7K | 102.5K | 248.6K | 470.6K | — | 11.8K | 1.23M | 58.32% | ↗ |
| 62 | 2018 | Alexander A. Santini Former Executive Vice President and Chief Commercial Officer | 399.7K | 102.5K | 248.6K | 470.6K | — | 11.8K | 1.23M | 58.32% | ↗ |
| 63 | 2018 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 384.7K | 123.7K | 243.7K | 457.5K | — | 11.8K | 1.22M | 57.41% | ↗ |
| 64 | 2018 | Brian T. Crum Vice President and General Counsel | 350.7K | 116.9K | 150.3K | 150.7K | — | 11.7K | 780.3K | 38.58% | ↗ |
| 65 | 2017 | Lonnel Coats President, Chief Executive Officer and Director | 618.3K | 392.6K | 309.7K | 879.8K | — | 11.8K | 2.21M | 53.77% | ↗ |
| 66 | 2017 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 454.4K | 165.6K | 172.7K | 490.9K | — | 11.7K | 1.30M | 51.23% | ↗ |
| 67 | 2017 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 427.0K | 155.0K | 161.6K | 459.2K | — | 11.7K | 1.21M | 51.12% | ↗ |
| 68 | 2017 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 394.6K | 100.2K | 149.3K | 424.3K | — | 11.6K | 1.08M | 53.11% | ↗ |
| 69 | 2017 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 393.8K | 93.3K | 149.7K | 425.3K | — | 11.6K | 1.07M | 53.55% | ↗ |
| 70 | 2016 | Lonnel Coats President, Chief Executive Officer and Director | 597.6K | 444.7K | 275.2K | 850.4K | — | 6.8K | 2.17M | 51.76% | ↗ |
| 71 | 2016 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 278.5K | 182.5K | — | 942.9K | — | 26.4K | 1.43M | 65.92% | ↗ |
| 72 | 2016 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 416.8K | 182.4K | 147.4K | 455.8K | — | 11.2K | 1.21M | 49.71% | ↗ |
| 73 | 2016 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 385.9K | 144.4K | 138.7K | 428.5K | — | 11.2K | 1.11M | 51.16% | ↗ |
| 74 | 2016 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 369.2K | 138.0K | 134.0K | 414.0K | — | 11.1K | 1.07M | 51.39% | ↗ |
| 75 | 2016 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 313.6K | 162.0K | 77.2K | 139.1K | — | 11.1K | 702.9K | 30.77% | ↗ |
| 76 | 2015 | Lonnel Coats President, Chief Executive Officer and Director | 561.8K | 439.9K | 270.0K | 826.9K | — | 720.00 | 2.10M | 52.25% | ↗ |
| 77 | 2015 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 401.2K | 238.1K | 144.7K | 443.2K | — | 7.2K | 1.23M | 47.62% | ↗ |
| 78 | 2015 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 361.0K | 121.3K | 131.4K | 402.3K | — | 7.2K | 1.02M | 52.16% | ↗ |
| 79 | 2015 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 378.0K | 125.6K | 113.4K | 347.2K | — | 7.2K | 971.4K | 47.42% | ↗ |
| 80 | 2015 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 378.0K | 125.6K | 113.4K | 347.2K | — | 7.2K | 971.4K | 47.42% | ↗ |
| 81 | 2015 | John P. Northcott Former Executive Vice President and Chief Commercial Offer | 312.4K | — | 107.3K | 328.7K | — | 26.1K | 774.5K | 56.30% | ↗ |
| 82 | 2015 | James F. Tessmer Vice President of Finance and Accounting | 252.2K | 63.9K | 66.5K | 118.8K | — | 7.0K | 508.3K | 36.44% | ↗ |
| 83 | 2015 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 201.4K | 58.0K | — | 64.1K | — | 5.4K | 328.9K | 19.50% | ↗ |
| 84 | 2014 | Lonnel Coats President, Chief Executive Officer and Director | 266.9K | 165.0K | — | 1.10M | — | 300.00 | 1.53M | 71.78% | ↗ |
| 85 | 2014 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 393.0K | 141.5K | 141.0K | 432.8K | — | 7.1K | 1.12M | 51.45% | ↗ |
| 86 | 2014 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 375.0K | 70.4K | 135.9K | 416.9K | — | 7.0K | 1.01M | 55.00% | ↗ |
| 87 | 2014 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 375.0K | 70.4K | 135.9K | 416.9K | — | 7.0K | 1.01M | 55.00% | ↗ |
| 88 | 2014 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 357.0K | 100.0K | 129.0K | 395.8K | — | 7.0K | 988.8K | 53.08% | ↗ |
| 89 | 2013 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580.0K | — | 292.6K | — | — | 7.1K | 1.77M | 16.52% | ↗ |
| 90 | 2013 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 406.7K | — | 167.2K | — | — | 6.5K | 1.09M | 15.34% | ↗ |
| 91 | 2013 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative Officer | 391.7K | — | 142.1K | 432.9K | — | 6.9K | 973.6K | 59.06% | ↗ |
| 92 | 2013 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 391.7K | — | 142.1K | — | — | 6.9K | 973.6K | 14.60% | ↗ |
| 93 | 2013 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 370.0K | — | 146.3K | — | — | 6.9K | 968.9K | 15.10% | ↗ |
| 94 | 2013 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 370.0K | — | 146.3K | 445.6K | — | 6.9K | 968.9K | 61.10% | ↗ |
| 95 | 2013 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 355.8K | — | 137.9K | 420.2K | — | 6.9K | 920.8K | 60.61% | ↗ |
| 96 | 2013 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 355.8K | — | 137.9K | — | — | 6.9K | 920.8K | 14.98% | ↗ |
| 97 | 2012 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580.0K | 215.0K | 266.4K | — | — | 7.0K | 1.88M | 14.18% | ↗ |
| 98 | 2012 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400.0K | 120.0K | 154.8K | — | — | 6.8K | 1.15M | 13.43% | ↗ |
| 99 | 2012 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385.0K | 100.0K | 140.4K | — | — | 6.8K | 1.06M | 13.26% | ↗ |
| 100 | 2012 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350.0K | 90.0K | 126.0K | — | — | 6.8K | 955.9K | 13.18% | ↗ |
| 101 | 2012 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 345.0K | 100.0K | 93.6K | — | — | 6.7K | 830.0K | 11.28% | ↗ |
| 102 | 2012 | Pablo Lapuerta, M.D. Executive Vice President, | 345.0K | 100.0K | 93.6K | — | — | 6.7K | 830.0K | 11.28% | ↗ |
| 103 | 2011 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580.0K | 195.0K | 332.5K | — | — | 6.8K | 1.92M | 17.33% | ↗ |
| 104 | 2011 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400.0K | 115.0K | 201.4K | — | — | 6.7K | 1.19M | 16.86% | ↗ |
| 105 | 2011 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385.0K | 105.0K | 170.8K | — | — | 6.7K | 1.08M | 15.76% | ↗ |
| 106 | 2011 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350.0K | 80.0K | 152.7K | — | — | 6.6K | 949.6K | 16.07% | ↗ |
| 107 | 2011 | Pablo Lapuerta, M.D. Executive Vice President, | 268.0K | 55.0K | — | — | — | 6.5K | 592.4K | 0.00% | ↗ |
| 108 | 2011 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 268.0K | 55.0K | — | — | — | 6.5K | 592.4K | 0.00% | ↗ |
| 109 | 2011 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 268.0K | 55.0K | — | — | — | 6.5K | 592.4K | 0.00% | ↗ |
| 110 | 2010 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 577.5K | 70.0K | 140.0K | — | — | 6.9K | 1.92M | 7.29% | ↗ |
| 111 | 2010 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 395.6K | 47.5K | 80.0K | — | — | 6.7K | 1.19M | 6.71% | ↗ |
| 112 | 2010 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 374.4K | 35.0K | 60.0K | — | — | 6.7K | 1.15M | 5.24% | ↗ |
| 113 | 2010 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 348.8K | 35.0K | 60.0K | — | — | 6.6K | 929.4K | 6.46% | ↗ |
| 114 | 2010 | Philip M. Brown, M.D., J.D. | 267.3K | — | 50.0K | — | — | 70.3K | 682.3K | 7.32% | ↗ |
| 115 | 2010 | James F. Tessmer Vice President, Finance and Accounting | 233.8K | 12.5K | 25.1K | — | — | 6.5K | 425.2K | 5.90% | ↗ |
| 116 | 2010 | Steven A. Tragash | 252.5K | 38.3K | 20.0K | — | — | 3.8K | 425.0K | 4.69% | ↗ |
| 117 | 2010 | Ajay Bansal Former Executive Vice President, | 7.8K | — | — | — | — | 333.6K | 341.5K | 0.00% | ↗ |
| 118 | 2009 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 560.0K | 210.0K | 149.9K | — | — | 7.0K | 1.77M | 8.48% | ↗ |
| 119 | 2009 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 365.0K | 120.0K | 80.0K | — | — | 6.7K | 1.06M | 7.55% | ↗ |
| 120 | 2009 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 340.0K | 90.0K | 65.0K | — | — | 6.7K | 908.7K | 7.15% | ↗ |
| 121 | 2009 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 340.0K | 90.0K | 65.0K | — | — | 6.7K | 908.7K | 7.15% | ↗ |
| 122 | 2009 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 340.0K | 90.0K | 65.0K | — | — | 6.7K | 854.4K | 7.60% | ↗ |
| 123 | 2009 | Ajay Bansal Former Executive Vice President, | 198.3K | — | — | — | — | 94.3K | 584.7K | 0.00% | ↗ |
| 124 | 2009 | Ajay Bansal | 198.3K | — | — | — | — | 94.3K | 584.7K | 0.00% | ↗ |
| 125 | 2009 | James F. Tessmer Vice President, Finance and Accounting | 225.0K | 45.0K | 34.9K | — | — | 6.0K | 473.8K | 7.38% | ↗ |
| 126 | 2008 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 557.5K | — | — | — | — | 6.5K | 1.44M | 0.00% | ↗ |
| 127 | 2008 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 363.3K | — | — | — | — | 6.3K | 938.7K | 0.00% | ↗ |
| 128 | 2008 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 115.4K | — | — | — | — | 350.5K | 749.4K | 0.00% | ↗ |
| 129 | 2008 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 338.8K | — | — | — | — | 6.2K | 648.5K | 0.00% | ↗ |
| 130 | 2008 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 338.3K | — | — | — | — | 6.2K | 648.1K | 0.00% | ↗ |
| 131 | 2008 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 338.3K | — | — | — | — | 6.2K | 648.1K | 0.00% | ↗ |
| 132 | 2008 | James F. Tessmer Vice President, Finance and Accounting | 224.6K | — | — | — | — | 6.1K | 291.4K | 0.00% | ↗ |
| 133 | 2008 | James F. Tessmer Vice President, Finance and Accounting | 224.6K | — | 16.4K | — | — | 6.1K | 290.8K | 5.65% | ↗ |
| 134 | 2007 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 522.9K | 265.0K | — | — | — | 6.3K | 1.79M | 0.00% | ↗ |
| 135 | 2007 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 340.9K | 140.0K | — | — | — | 6.1K | 1.07M | 0.00% | ↗ |
| 136 | 2007 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 316.5K | 130.0K | — | — | — | 6.1K | 805.4K | 0.00% | ↗ |
| 137 | 2007 | Julia P. Gregory Executive Vice President and Chief Financial Officer | 334.3K | 120.0K | — | — | — | 6.1K | 804.5K | 0.00% | ↗ |
| 138 | 2007 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 334.3K | 120.0K | — | — | — | 6.1K | 804.5K | 0.00% | ↗ |
| 139 | 2007 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 323.4K | 130.0K | — | — | — | 6.1K | 753.4K | 0.00% | ↗ |
| 140 | 2006 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 473.0K | 300.0K | — | — | — | 373.5K | 1.94M | 0.00% | ↗ |
| 141 | 2006 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 312.0K | 120.0K | — | — | — | 5.9K | 800.4K | 0.00% | ↗ |
| 142 | 2006 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 329.0K | 80.0K | — | — | — | 6.0K | 747.1K | 0.00% | ↗ |
| 143 | 2006 | Julia P. Gregory Executive Vice President and Chief Financial Officer | 329.0K | 80.0K | — | — | — | 6.0K | 747.1K | 0.00% | ↗ |
| 144 | 2006 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 292.0K | 80.0K | — | — | — | 5.9K | 668.6K | 0.00% | ↗ |
| 145 | 2006 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 312.0K | 90.0K | — | — | — | 5.9K | 628.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Exton | Chief Executive Officer & Director | 1M | — |
| Craig Granowitz | Senior Vice President & Chief Medical Officer | 789.5K | — |
| Brian T. Crum | Senior Vice President, General Counsel & Secretary | 687.4K | male |
| Scott Coiante | Senior Vice President & Chief Financial Officer | 646.3K | male |
| Wendy E. McDermott | Senior Vice President of Human Resources | 580.4K | female |
| Kristen L. Alexander | Vice President of Finance & Accounting | 379.8K | female |
| Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | — | female |
| Dixon Terry | Vice President of Compliance | — | male |
| Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy | — | female |
| Desiree Gendron | Vice President of Sales & Training | — | female |
| Suma Gopinathan | Senior Vice President of Discovery | — | — |
| Carrie Siragusa | Vice President of Marketing | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LXRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
